Evidence map›Paper›PMID 41897383›Full record

ReviewBiomolecules2026

PAX3: A Driver of Normal Development and Disease.

Noah B Prince, Joyce H Liang, Theresa M Rosato, Deborah Lang

Abstract readReview
In one paragraph

Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Noah B PrinceDepartment of Dermatology, Boston University, Boston, MA 02118, USA.
Joyce H LiangDepartment of Dermatology, Boston University, Boston, MA 02118, USA.
Theresa M RosatoDepartment of Dermatology, Boston University, Boston, MA 02118, USA.
Deborah LangDepartment of Dermatology, Boston University, Boston, MA 02118, USA.ORCID 0000-0003-1057-0923

Funding

American Cancer Society DBG-23-1152683-01-RMCAmerican Cancer Society POST-BACC-23-1158414-01-DPBACCLEO Foundation LF-OC-21-00088National Institute of Health 1R03CA288281-01A1
6 · The paper itself

Abstract

PAX3 plays a vital role in regulating proper growth, migration, differentiation, and survival during development of normal tissues, including those derived from the embryonic neural crest. PAX3 is a transcription factor with two separate DNA-binding domains and can positively (and less frequently, negatively) regulate gene expression. The levels of PAX3 can be modified by upstream molecular pathways, and its subsequent downstream functions are regulated through a wide range of protein interactions and posttranscriptional modifications. PAX3 direct downstream target genes are other transcription regulators and factors that modulate cellular proliferation, lineage specificity, migration, and survival. The pathways that PAX3 regulates during development may be recycled and subverted during disease progression, for example, during cancer progression, growth, and metastasis. Indeed, PAX3 is overexpressed in several cancers, including melanoma, neuroblastoma, and rhabdomyosarcoma. While there is still much that is unknown about the mechanisms by which PAX3 controls such a wide array of key cellular functions, a great deal of progress has been made to advance our understanding of this critical and multi-faceted factor.

Indexed as

NeoplasmsPAX3 Transcription FactorAnimalsGene Expression Regulation, NeoplasticHumansMelanomaNeural CrestPAX3 protein, humanPAX3 Transcription Factormelanocytemelanomaneural crestPAX3PAX proteinstranscription factor

Identifiers

PMID41897383
PMCPMC13024339

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.